Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENHANCE: Phase 2 randomized double-blind study of BRII-179 + BRII-835 + peginterferon alfa in chronic hepatitis B
CTR20243850Phase 2Active
- Sponsor
- Brii Biosciences
- Start
- Oct 2024
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BRII-179, elebsiran, peginterferon alfa-2b in Chronic Hepatitis B (CHB), sponsored by Brii Biosciences. Started Oct 2024; status: active.
02
Drugs
BRII-179elebsiranpeginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20243850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243850.